Pharmaceuticals

Machine Learning (ML) in The Pharmaceutical Industry Market Trends, Drivers, and Regional Analysis 2025–2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the machine learning (ml) in the pharmaceutical industry market from 2025–2034 with trusted insights from The Business Research Company

How Is The Machine Learning (ML) in The Pharmaceutical Industry Market Size Expected To Expand Over 2029-2034?

The vesicular monoamine transporter 2 (vmat2) inhibitor market size has experienced rapid expansion in recent years. It is projected to increase from $1.13 billion in 2024 to $1.25 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.3%. The growth observed during the historical period can be attributed to several factors, including the increasing occurrence of movement disorders, a heightened demand for effective therapeutic choices, rising public awareness concerning tardive dyskinesia, the expanding global geriatric population, and a growing preference for oral drug formulations.

The market for vesicular monoamine transporter 2 (vmat2) inhibitors is anticipated to experience swift expansion over the coming years. This market is projected to reach $1.83 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.1%. The expansion anticipated during the forecast period is attributable to several factors, including the increasing occurrence of neurodegenerative conditions, greater utilization of targeted treatments, a heightened emphasis on personalized medical approaches, augmented investment in research and development, and enhanced public understanding of psychiatric and movement disorders. Key trends expected within this period encompass progress in neurological research, innovations in drug formulations, a move towards personalized and precision medical practices, the creation of advanced VMAT2 inhibitors, and the incorporation of digital health technologies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp

Which Market Factors Are Fueling The Machine Learning (ML) in The Pharmaceutical Industry Industry Growth?

The rising incidence of Parkinson’s disease is anticipated to boost the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market in the future. Parkinson’s disease is defined as a progressive neurological condition impacting movement, resulting from the depletion of dopamine-producing cells within the brain. The growing occurrence of Parkinson’s disease primarily stems from an aging population, enhanced diagnostic methods, environmental elements like toxins, genetic factors, and improved understanding of the illness. VMAT2 inhibitors are instrumental in alleviating Parkinson’s symptoms by regulating dopamine release and diminishing tremors and dyskinesia. As an illustration, in December 2022, data from the Parkinson’s Foundation, a US-based nonprofit organization, indicated that approximately 90,000 individuals were diagnosed with Parkinson’s disease in the U.S., representing a 50% rise from the prior estimate of 60,000 yearly diagnoses. Consequently, the heightened prevalence of Parkinson’s disease is fueling growth in the vesicular monoamine transporter 2 (VMAT2) inhibitor market.

Which Categories Are Covered In The Machine Learning (ML) in The Pharmaceutical Industry Market Segmentation Analysis?

The vesicular monoamine transporter 2 (vmat2) inhibitor market covered in this report is segmented –

1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs

2) By Route Of Administration: Oral, Other Administrations

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment

2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders

3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders

4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

Which Market Trends Are Expected To Define The Future Of The Machine Learning (ML) in The Pharmaceutical Industry Market?

Leading companies in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are prioritizing the creation of innovative formulations, such as capsules, to enhance patient adherence, improve drug stability, and optimize therapeutic effectiveness. Capsules, a solid dosage form contained within a gelatin or HPMC shell, aid VMAT2 inhibitors by boosting drug stability, ensuring precise dosing, and improving patient compliance. As an illustration, in July 2024, Neurocrine Biosciences Inc., a US-based biopharmaceutical company, introduced Ingrezza Sprinkle (valbenazine) capsules. This is a new formulation of the VMAT2 inhibitor Ingrezza, developed to simplify administration for adults with tardive dyskinesia and chorea associated with Huntington’s disease who experience dysphagia or difficulty swallowing. Ingrezza Sprinkle delivers the same effective dosing options as Ingrezza and can be administered either by sprinkling the capsule’s contents onto soft food or by swallowing the capsule intact.

Which Organizations Are At The Forefront Of The Machine Learning (ML) in The Pharmaceutical Industry Market?

Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/vesicular-monoamine-transporter-2-vmat2-inhibitor-global-market-report

Which Geographic Areas Are Driving Strong Demand For The Machine Learning (ML) in The Pharmaceutical Industry Market?

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21317&type=smp

Browse Through More Reports Similar to the Global Machine Learning (ML) in The Pharmaceutical Industry Market 2025, By The Business Research Company

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Tyrosine Kinase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Interleukin Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795